European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics – Update 2019
Claus Garbe(University of Tübingen), Alexander M.M. Eggermont(University Medical Center Utrecht), Véronique Bataille(King's College London), Ricardo Vieira(Hospitais da Universidade de Coimbra), D. Moreno‐Ramírez(Hospital Universitario Virgen Macarena), Célèste Lebbé(Inserm), Petr Arenberger(Charles University), Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), Roland Kaufmann(Robert Koch Institute), Axel Hauschild(University Hospital Schleswig-Holstein), Josep Malvehy(Universitat de Barcelona), Mark R. Middleton(University of Oxford), Maria Concetta Fargnoli(University of L'Aquila), Teresa Amaral(University Children's Hospital Tübingen), Aimilios Lallas(Aristotle University of Thessaloniki), Lars Bastholt(Odense University Hospital), V. del Mármol(Université Libre de Bruxelles), Iris Zalaudek(Azienda Sanitaria Universitaria Integrata di Trieste), Alexander J. Stratigos(National and Kapodistrian University of Athens), Ketty Peris(Università Cattolica del Sacro Cuore), Christoph Höller(Medical University of Vienna), Giovanni Pellacani(Sapienza University of Rome), Jean-Jacques Grob(Aix-Marseille Université), Brigitte Dréno(Nantes Université)
Cited by 191
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.8k